Fact CheckerSign in

NCT06594367Completed

A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province

Source: ClinicalTrials.gov · Last updated 23 Mar 2026

Brief summary (registry, in English)

This is an observational study aimed at assessing if a new and specific heterozygous deletion detected at PKD2 gene is associated to a "founder effect" in 10 Autosomal dominant polycystic kidney disease (ADPKD) patients, and at investigating the genotype-phenotype correlation in the families sharing the same PKD2 breakpoint site.

Status (registry)
Completed
Study type
Observational
Enrollment
10 (actual)
First submitted
2 Sept 2024
Start date
22 Jan 2025
Primary completion date
17 Oct 2025
Lead sponsor
Mario Negri Institute for Pharmacological Research
NCT number
NCT06594367

What you commit to

  • Study type: Observational
  • Participants enrolled: 10
  • From 22 Jan 2025 to the primary completion date, 17 Oct 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Healthy patients

Who the study is looking for

  • Patients with ADPKD

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Coordinator of this site? Confirm its status
RanicaItalyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.